Collaboration to validate next-generation tests for detection of primary and recurrent/metastatic cancer and personalized treatment response prediction.
Partnership aims to enhance precision oncology through advanced novel biomarker-driven diagnostics.
Bengaluru, India 18 November 2024 – HealthCare Global Enterprises Limited (HCG), India’s leading provider of cancer careannounced a research collaboration with Trucan Diagnostics Pvt Ltd, a pioneering startup specializing in advanced cancer diagnostics. This partnership aims to validate a suite of novel diagnostic tests designed to improvedetection of primary and recurrent/metastatic cancer precisely, predict therapy responses, and monitor treatment efficacy.
Under this partnership, HCG and Trucan will work together to conduct extensive validation studies on a new set of cancer diagnostic tests developed by Trucan. These tests employ advanced techniques, including next-generation sequencing and novel biomarker-driven diagnostics, to enable preciseprimary, recurrent/metastatic cancer detection, pre-treatment prediction of responseto therapy and monitoring patients undergoing chemo or targeted therapy. The results of these studies will generate necessary data to assess and confirm the clinical utility of these tests,paving the way for their potential integration into routine clinical practice.
The novel biomarker driven cancer detection methods developed by Trucan will pioneer a significant improvement over current methods. By accurately predicting a patient’s response to therapy, these diagnostic tests aim to empower oncologists to personalize treatment plans, minimize ineffective therapies and associated morbidity while reducing overall treatment costs.
Dr. B. S. Ajaikumar, Executive Chairman,Healthcare Global Enterprises Limited, commented, “At HCG, our mission has always been to lead with innovation and compassion, especially in the fight against cancer. This collaboration with Trucan Diagnostics is a significant step forward in advancing India’s capabilities in precision oncology. By validating next-generation diagnostic tools developedin our Genomics laboratory at Triesta Sciences, we are not only aiming to enhance detection but also to offer highly personalized treatment planning that addresses each patient’s unique cancer profile. These innovations align with our vision to make cutting-edge, effective cancer care accessible, ultimately improving survival rates and quality of life for patients across the country.”
Adding to this, Dr. Raman Govindarajan, Founder& CEO of Trucan Diagnostics, said, “Partnering with HCG gives us a tremendous opportunity to validate our novel diagnostic solutions in a real-world setting. We are optimistic that the outcomes of this collaboration will contribute significantly to our mission of advancing precision oncology, optimizing patient care and improving overall outcome for patients with cancer.”
This research partnership highlights HCG and Trucan’s commitment to advancing oncology diagnostics and establishing a strong evidence base for new technologies. Through their combined expertise, the organizations aim to generate valuable insights that can pave the way for improved cancer care and outcomes.
